

## **AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

### **Listing of the Claims:**

1-33 (canceled).

34 (original). A method of treating a disease or disorder in a subject comprising administering to a subject in need of such treatment a therapeutically effective amount of a molecule which antagonizes the function of a Notch protein.

Claim 35-89 (canceled).

90 (new). The method according to claim 34, in which the disease or disorder is a malignancy characterized by increased Notch activity or increased expression of a Notch protein or of a Notch derivative capable of being bound by an anti-Notch antibody, relative to said Notch activity or expression in an analogous non-malignant sample.

91 (new). The method according to claim 34, in which the disease or disorder is cervical cancer.

92 (new). The method according to claim 34, in which the disease or disorder is breast cancer.

93 (new). The method according to claim 34, in which the disease or disorder is colon cancer.

94 (new). The method according to claim 90, in which the malignancy is selected from the group consisting of melanoma, seminoma, and lung cancer.

95 (new). The method according to claim 34, 90, 91, 92 or 93, in which the subject is a human.

96 (new). The method according to claim 34, 91, 92 or 93, in which the molecule is an antibody to Notch or a portion of said antibody containing the idiotype thereof.

97 (new). The method according to claim 96, in which the antibody is a neutralizing antibody.

98 (new). The method according to claim 96, in which the antibody is monoclonal.

99 (new). The method according to claim 97, in which the neutralizing antibody is monoclonal.

100 (new). The method according to claim 97, in which the neutralizing antibody or portion of said antibody containing the idiotype thereof binds to a human Notch protein but does not bind to a *Drosophila* Notch protein.

101 (new). The method according to claim 34, 91, 92 or 93, in which the molecule is a protein consisting of at least the extracellular domain of a Notch protein or a portion thereof capable of binding to a Notch ligand.

102 (new). The method according to claim 34, 91, 92 or 93, in which the molecule is a protein consisting of at least the EGF homologous repeats of a Notch protein.

103 (new). The method according to claim 34, 91, 92 or 93, in which the molecule is a protein consisting of at least the EGF-like repeats 11 and 12 of a Notch protein.

104 (new). The method according to claim 34, 91, 92 or 93, in which the molecule is a protein consisting of at least an adhesive fragment of a Notch protein, the fragment being characterized by the ability to bind to a toporythmic protein.

105 (new). The method according to claim 34, 91, 92 or 93, in which the molecule is an oligonucleotide which (a) consists of at least six nucleotides; (b) consists of at least a sequence complementary to at least a portion of a RNA transcript of a Notch gene; and (c) is hybridizable to the RNA transcript.

106 (new). The method according to claim 34, in which the molecule is an antibody to a toporythmic protein, or a portion of the antibody containing the idiotype thereof.

107 (new). The method according to claim 106, in which the toporythmic protein is Delta, Serrate or Notch.

108 (new). The method according to claim 106, in which the antibody binds to a fragment of a toporythmic protein, the fragment being characterized by the ability to bind to a Notch protein.

109 (new). The method according to claim 106, in which the antibody is monoclonal.

110 (new). The method according to claim 106, in which the antibody is a neutralizing antibody.

111 (new). The method according to claim 34, in which the molecule is a protein consisting of at least a fragment of a toporythmic protein, the fragment being characterized by the ability to bind to a Notch protein.

112 (new). The method according to claim 111, in which the toporythmic protein is Delta or Serrate.

113 (new). The method according to claim 34, in which the molecule is a Notch protein.

114 (new). The method according to claim 34, in which the molecule is encoded by a gene which is a member of the Notch signaling pathway.

115 (new). The method according to claim 34, in which the molecule interferes with Notch intracellular signal transduction.

116 (new). The method according to claim 34, in which the molecule is an analog or competitive inhibitor of a Notch intracellular signal transducing region.